SCHEMBL1876284

SCHEMBL1876284

CCc1c(C=O)c(C(=O)OC)c(C(C)C)n1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.46
ALDH1A1 P00352 4/20 0.43
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
S1PR3 Q99500 7/20 0.43
MAPT P10636 3/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
THRB P10828 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
PLA2G2A P14555 3/20 0.39
PLA2G10 O15496 1/20 0.39
PLA2G1B P04054 1/20 0.39
PLA2G5 P39877 1/20 0.39
PLA2G2F Q9BZM2 1/20 0.39
PLA2G2E Q9NZK7 1/20 0.39
PLA2G2D Q9UNK4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1882164 0.91 AR (0.46) ARALDH1A1S1PR3MAPTGAA
SCHEMBL1884629 0.88 AR (0.43) ARALDH1A1S1PR3MAPTGAA
SCHEMBL1884630 0.88 AR (0.43) ARALDH1A1S1PR3MAPTGAA
SCHEMBL12638315 0.84 AR (0.47) ARALDH1A1S1PR3MAPTGAA
SCHEMBL1884196 0.80 AR (0.46) ARALDH1A1S1PR3MAPTGAA
SCHEMBL1890367 0.72 GAA (0.48) ARALDH1A1NPSR1MAPTGAA
SCHEMBL1880402 0.71 MAPT (0.46) ARALDH1A1NPSR1S1PR3MAPT
SCHEMBL336671 0.71 MAPT (0.73) ARALDH1A1LMNAS1PR3MAPT
SCHEMBL1884473 0.70 MEN1 (0.43) LMNAS1PR3PLA2G2A
SCHEMBL337183 0.70 PLA2G2A (0.59) ALDH1A1S1PR3MAPTGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity ALLERGAN, INC. (US) 2011-05-05 US disclosed
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity ALLERGAN, INC. (US) 2011-05-05 US disclosed
EP-2185506-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY Allergan, Inc. (US) 2010-05-19 EP disclosed
WO-2009026407-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2009-02-26 WO disclosed
WO-2009026407-A1 PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105567-A1 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity S1PR1, S1PR2, S1PR3 AR 1533/4885ALDH1A1 2936/4885LMNA 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.